148 related articles for article (PubMed ID: 22585285)
1. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.
Shoaf SE; Kim SR; Bricmont P; Mallikaarjun S
Eur J Clin Pharmacol; 2012 Dec; 68(12):1595-603. PubMed ID: 22585285
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
[TBL] [Abstract][Full Text] [Related]
3. Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.
Shoaf SE; Mallikaarjun S; Bricmont P
Eur J Clin Pharmacol; 2012 Feb; 68(2):207-11. PubMed ID: 21853290
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men.
Yi S; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Apr; 59(4):315-22. PubMed ID: 22130104
[TBL] [Abstract][Full Text] [Related]
6. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects.
Disanto AR; Golden G
Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
[TBL] [Abstract][Full Text] [Related]
8. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):150-6. PubMed ID: 22257581
[TBL] [Abstract][Full Text] [Related]
9. Phase III clinical pharmacology study of tolvaptan.
Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
Kida K; Shibagaki Y; Tominaga N; Matsumoto N; Akashi YJ; Miyake F; Kimura K
Clin Pharmacokinet; 2015 Mar; 54(3):273-84. PubMed ID: 25305049
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
12. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.
Warrington S; Nagakawa S; Hounslow N
Clin Drug Investig; 2011 Oct; 31(10):735-43. PubMed ID: 21877766
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
Shoaf SE; Wang Z; Bricmont P; Mallikaarjun S
J Clin Pharmacol; 2007 Dec; 47(12):1498-507. PubMed ID: 17925589
[TBL] [Abstract][Full Text] [Related]
15. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
Shoaf SE; Bricmont P; Mallikaarjun S
Kidney Int; 2014 Apr; 85(4):953-61. PubMed ID: 24048380
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.
Inoue K; Shishido A; Vaccaro N; Jiao J; Stieltjes H; Bernard A; Yu M; Chien C
Cancer Chemother Pharmacol; 2015 Jan; 75(1):49-58. PubMed ID: 25344090
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias.
Shoaf SE; Elizari MV; Wang Z; Sekar K; Grinfeld LR; Barbagelata NA; Lerman J; Bramer SL; Trongé J; Orlandi C
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):165-71. PubMed ID: 16211205
[TBL] [Abstract][Full Text] [Related]
20. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.
Taubel J; Ferber G; Lorch U; Batchvarov V; Savelieva I; Camm AJ
Br J Clin Pharmacol; 2014 Jan; 77(1):170-9. PubMed ID: 23713767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
